YL 0010
Alternative Names: YL-0010Latest Information Update: 08 Oct 2021
At a glance
- Originator Shenzhen Ionova Life Sciences Co., Ltd.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Oct 2021 New profile has been created from Shenzhen Ionova Life Sciences' pipeline
- 07 Oct 2021 Preclinical trials in Solid tumours in USA (unspecified route) before October 2021 (Shenzhen Ionova Life Sciences' pipeline, October 2021)